Lerociclib

Lerociclib

Lerociclib is a differentiated oral CDK4/6 inhibitor with potential use in combination with other targeted therapies in certain types of breast and lung cancer.

At the San Antonio Breast Cancer Synmposium (SABCS) in December 2019, we reported preliminary Phase 1/2 data on the differentiated safety and tolerability profile of lerociclib, along with preliminary efficacy findings that were consistent with other CDK4/6 inhibitors used in combination with fulvestrant. 

Lerociclib is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with fulvestrant for patients with ER+, HER2- breast cancer (NCT02983071) and in epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NCT03455829).